An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

Last updated:
2026-10-03
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A SINGLE ARM, MULTICENTER, OPEN-LABEL EXTENSION (OLE) TRIAL TO EVALUATE LONG-TERM SAFETY AND TOLERABILITY OF PELACARSEN (TQJ230) IN PARTICIPANTS WHO COMPLETED THE PARENT LP(A)HORIZON TRIAL

Intervention/treatment:
PELACARSEN (TQJ230)
Medical condition:
ELEVATED LEVELS OF LIPOPROTEIN
Protocol code:
CTQJ230A12301E1
Control number:
297235
Status:
Recruiting
Approved:
June 12, 2025
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT07517263
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 100 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Novartis Pharmaceuticals
Role
CONTACT
Phone:
1-888-669-6682
Name
Novartis Pharmaceuticals
Role
CONTACT
Phone:
+41613241111
Sponsor
NOVARTIS PHARMACEUTICALS CANADA INC

Locations

British Columbia

Novartis Investigative Site
Vancouver, British Columbia, V5Z 1M9
Active, not recruiting
Novartis Investigative Site
Vancouver, British Columbia, V6Z 2H2
Recruiting
Novartis Investigative Site
Victoria, British Columbia, V8R4R2
Recruiting
Novartis Investigative Site
Victoria, British Columbia, V8T 5G4
Recruiting

Ontario

Novartis Investigative Site
Oakville, Ontario, L6K 3W7
Recruiting
Novartis Investigative Site
Toronto, Ontario, M9V 4B4
Recruiting

Quebec

Novartis Investigative Site
Levis, Quebec, G6V 4Z5
Active, not recruiting
Novartis Investigative Site
Montreal, Quebec, H1T 1C8
Recruiting
Novartis Investigative Site
Montreal, Quebec, H2X 1R9
Active, not recruiting
Novartis Investigative Site
Montreal, Quebec, H3T 1E2
Recruiting
Novartis Investigative Site
Montreal, Quebec, H4A 3J1
Recruiting
Novartis Investigative Site
Quebec, Quebec, G1R 2J6
Recruiting
Novartis Investigative Site
Quebec, Quebec, G1V 4G5
Active, not recruiting
Novartis Investigative Site
Quebec, Quebec, G1V 4W2
Active, not recruiting
Did you find what you were looking for?